Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
School of Engineering, University of British Columbia, Kelowna, BC, Canada.
Cell Host Microbe. 2023 May 10;31(5):695-711. doi: 10.1016/j.chom.2023.03.019.
Fecal microbiota transplantation (FMT) is highly effective in preventing recurrent Clostridioides difficile infection (rCDI). However, the mechanisms underpinning its clinical efficacy are incompletely understood. Herein, we provide an overview of rCDI pathogenesis followed by a discussion of potential mechanisms of action focusing on the current understanding of trans-kingdom microbial, metabolic, immunological, and epigenetic mechanisms. We then outline the current research gaps and offer methodological recommendations for future studies to elevate the quality of research and advance knowledge translation. By combining interventional trials with multiomics technology and host and environmental factors, analyzing longitudinally collected biospecimens will generate results that can be validated with animal and other models. Collectively, this will confirm causality and improve translation, ultimately to develop targeted therapies to replace FMT.
粪便微生物移植(FMT)在预防复发性艰难梭菌感染(rCDI)方面非常有效。然而,其临床疗效的机制尚不完全清楚。在此,我们首先概述 rCDI 的发病机制,然后讨论潜在的作用机制,重点是当前对跨王国微生物、代谢、免疫和表观遗传机制的理解。然后,我们概述了当前的研究空白,并为未来的研究提供方法学建议,以提高研究质量并推进知识转化。通过将干预性试验与多组学技术以及宿主和环境因素相结合,对纵向采集的生物样本进行分析,将产生可与动物和其他模型验证的结果。总之,这将确认因果关系并提高转化水平,最终开发出靶向治疗方法来替代 FMT。